These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 30542701)

  • 21. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
    Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U
    Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.
    Li Y; Tian Z; Rizvi SM; Bander NH; Allen BJ
    Prostate Cancer Prostatic Dis; 2002; 5(1):36-46. PubMed ID: 15195129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors.
    Weber JS; Vogelzang NJ; Ernstoff MS; Goodman OB; Cranmer LD; Marshall JL; Miles S; Rosario D; Diamond DC; Qiu Z; Obrocea M; Bot A
    J Immunother; 2011 Sep; 34(7):556-67. PubMed ID: 21760528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CAR T Cell Therapy in Pancreaticobiliary Cancers: a Focused Review of Clinical Data.
    Anwar MY; Williams GR; Paluri RK
    J Gastrointest Cancer; 2021 Mar; 52(1):1-10. PubMed ID: 32700185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chimeric antigen receptor T cells: a novel therapy for solid tumors.
    Yu S; Li A; Liu Q; Li T; Yuan X; Han X; Wu K
    J Hematol Oncol; 2017 Mar; 10(1):78. PubMed ID: 28356156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancement of antitumour immunity by a novel chemotactic antigen DNA vaccine encoding chemokines and multiepitopes of prostate-tumour-associated antigens.
    Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S
    Immunology; 2006 Mar; 117(3):419-30. PubMed ID: 16476062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen.
    Slovin SF
    Expert Opin Ther Targets; 2005 Jun; 9(3):561-70. PubMed ID: 15948673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The therapeutic potential of a novel PSMA antibody and its IL-2 conjugate in prostate cancer.
    Sugimoto Y; Hirota M; Yoshikawa K; Sumitomo M; Nakamura K; Ueda R; Niwa R; Suzawa T; Yamasaki M; Shitara K; Kato T; Nakamura K
    Anticancer Res; 2014 Jan; 34(1):89-97. PubMed ID: 24403448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Advances in prostate-specific membrane antigen targeted therapies for prostate cancer].
    Wang W; Mo ZN
    Zhonghua Nan Ke Xue; 2010 Jun; 16(6):547-51. PubMed ID: 20608362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.
    DiPippo VA; Olson WC; Nguyen HM; Brown LG; Vessella RL; Corey E
    Prostate; 2015 Feb; 75(3):303-13. PubMed ID: 25327986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen.
    Huang X; Bennett M; Thorpe PE
    Prostate; 2004 Sep; 61(1):1-11. PubMed ID: 15287089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody-drug conjugates targeting prostate-specific membrane antigen.
    Olson WC; Israel RJ
    Front Biosci (Landmark Ed); 2014 Jan; 19(1):12-33. PubMed ID: 24389170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
    Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
    Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models.
    Zuccolotto G; Fracasso G; Merlo A; Montagner IM; Rondina M; Bobisse S; Figini M; Cingarlini S; Colombatti M; Zanovello P; Rosato A
    PLoS One; 2014; 9(10):e109427. PubMed ID: 25279468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.
    Milowsky MI; Nanus DM; Kostakoglu L; Sheehan CE; Vallabhajosula S; Goldsmith SJ; Ross JS; Bander NH
    J Clin Oncol; 2007 Feb; 25(5):540-7. PubMed ID: 17290063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues.
    Cunha AC; Weigle B; Kiessling A; Bachmann M; Rieber EP
    Cancer Lett; 2006 May; 236(2):229-38. PubMed ID: 16046056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial.
    Fuessel S; Meye A; Schmitz M; Zastrow S; Linné C; Richter K; Löbel B; Hakenberg OW; Hoelig K; Rieber EP; Wirth MP
    Prostate; 2006 Jun; 66(8):811-21. PubMed ID: 16482569
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy.
    Gong MC; Chang SS; Watt F; O'Keefe DS; Bacich DJ; Uchida A; Bander NH; Reuter VE; Gaudin PB; Molloy PL; Sadelian M; Heston WD
    Mol Urol; 2000; 4(3):217-22;discussion 223. PubMed ID: 11062377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.